Please use this identifier to cite or link to this item:
Title: The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma–COPD Overlap Syndrome
Author: Pérez de Llano, Luis
Dacal Rivas, David
Marina Malanda, Nuria
Plaza Moral, Vicente
Gullón Blanco, José Antonio
Muñoz Esquerre, Mariana
García Moguel, Ismael
Díaz Campos, Rocío M.
Martínez Moragón, Eva
Harbenau Mena, Alicia
Cosío, Borja G.
Padilla Galo, Alicia
Cisneros Serrano, Carolina
Keywords: Asma
Malalties pulmonars obstructives cròniques
Utilització de medicaments
Chronic obstructive pulmonary diseases
Drug utilization
Issue Date: 1-Mar-2022
Publisher: Informa UK Limited
Abstract: Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with >= 1 exacerbation and >= 1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of controlled patients (with no exacerbations, no need for corticosteroids and ACT >= 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.
Note: Reproducció del document publicat a:
It is part of: Journal of Asthma and Allergy, 2022, vol. 15, p. 363-369
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
jaa-15-363.pdf1.24 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons